mRNA HIV investigational
Selected indexed studies
- High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). (Ann Intern Med, 2025) [PMID:40294415]
- Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. (Science, 2020) [PMID:33060363]
- Prion-like low complexity regions enable avid virus-host interactions during HIV-1 infection. (Nat Commun, 2022) [PMID:36202818]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). (2025) pubmed
- Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. (2020) pubmed
- Prion-like low complexity regions enable avid virus-host interactions during HIV-1 infection. (2022) pubmed
- Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial. (2025) pubmed
- Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. (2024) pubmed
- Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019. (2025) pubmed
- COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis. (2024) pubmed
- Agents for treating human immunodeficiency virus infection. (1994) pubmed
- Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors. (2020) pubmed
- Modulation of rat cytochrome P-450 by an investigational HIV protease inhibitor. (1999) pubmed